Postoperative management of differentiated thyroid cancer.
Differentiated thyroid cancer is increasing in prevalence. This article discusses various aspects of the postoperative management of differentiated thyroid cancer including cancer staging, treatment, and monitoring. Treatment options discussed include radioactive iodine remnant ablation and levothyroxine suppression therapy. Recommendations are given for monitoring based on thyroglobulin determination and available imaging modalities.
Division of Endocrinology, Diabetes & Metabolism, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Amin
A
Sabet
Matthew
M
Kim
D000231:Adenocarcinoma, Papillary / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D018276:Carcinoma, Medullary / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000473:pathology / Q000628:therapy; D011182:Postoperative Care / Q000379:methods*; D011183:Postoperative Complications / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine